Nurix therapeutics presents positive clinical data from its novel bruton's tyrosine kinase (btk) degrader programs, nx-5948 and nx-2127, at the 65th american society of hematology (ash) annual meeting

Positive preliminary efficacy data with a favorable safety profile support plans to develop nx-5948 broadly in chronic lymphocytic leukemia (cll)

NRIX Ratings Summary

NRIX Quant Ranking